Cresilon's TRAUMAGEL Study: Breakthrough in Hemorrhage Control and Tourniquet Management

TRAUMAGEL Study: A Game Changer in Hemorrhage Control

Cresilon Inc., a biotechnology firm based in Brooklyn, has made remarkable strides in the realm of emergency medicine with the introduction of TRAUMAGEL, a hemostatic gel that has recently garnered attention for its effectiveness in managing traumatic extremity injuries. The company announced key insights from a peer-reviewed study detailing the impact of TRAUMAGEL on hemorrhage control and tourniquet management, published in the Summer 2026 issue of the Journal of Special Operations Medicine.

The Urgency of Hemorrhage Control

Hemorrhage is recognized as the leading cause of preventable deaths on the battlefield, accounting for over 90% of fatalities that could otherwise be survived. The ability to rapidly control bleeding is crucial for survival, especially in cases involving severe extremity injuries. Tourniquets are often employed as a first-line intervention to stem life-threatening blood loss. However, the use of tourniquets can pose risks, including tissue damage and nerve injury, particularly when they are applied for extended periods without definitive treatment.

Innovative Solutions for Prolonged Care

When evacuating patients is delayed or access to definitive treatment takes more time, it becomes imperative for medical personnel to find ways to maintain effective hemorrhage control while carefully transitioning patients off tourniquets. The latest study titled, "The Use of TRAUMAGEL for Hemorrhage Control and Tourniquet Removal — A Case Series of Traumatic Extremity Injuries," explored multiple cases—encompassing gunshot wounds, industrial accidents, and sharp-force injuries—where TRAUMAGEL was applied.

The findings are significant; in all the examined cases, TRAUMAGEL facilitated sustained hemorrhage control and allowed for the safe removal of tourniquets without rebleeding. This is an encouraging development, particularly in military and civilian trauma settings where time constraints often complicate emergency response efforts.

Joe Landolina, co-founder and CEO of Cresilon, emphasized the importance of these findings for trauma care. He stated, "Controlling severe bleeding is critical, but prolonged field care presents additional challenges when definitive treatment is delayed. Medical personnel must make crucial decisions about how to maintain hemorrhage control while safely transitioning patients off tourniquets. These findings help inform a vital aspect of trauma care and underscore the importance of having effective tools available when evacuation or definitive treatment is delayed."

TRAUMAGEL: The Innovative Technology

TRAUMAGEL utilizes Cresilon's proprietary hydrogel technology. It is designed to be user-friendly, supplied in a sterile 30 mL prefilled syringe that requires no preparation. This enables rapid application and removal, making it an invaluable tool for first responders and medical personnel. With the primary goal of stopping bleeding quickly, TRAUMAGEL represents a significant advancement as the first gel in a syringe specifically tailored for traumatic hemorrhage management.

Currently, TRAUMAGEL is actively used by more than 150 emergency medical services across the United States. The product has also received favorable considerations from the U.S. Department of Defense's Walter Reed Army Institute of Research and the U.S. Army Institute of Surgical Research, further validating its clinical efficacy.

Additionally, Cresilon has actively shared their research and clinical findings regarding TRAUMAGEL at several prestigious military and trauma medical forums, such as the Military Health System Research Symposium and the Special Operations Medical Association Scientific Assembly.

A Mission to Save Lives

Cresilon continues to pave the way for innovation in the field of hemostatic medical technologies. The company’s mission, centered on saving lives, resonates through all its efforts to improve trauma care. With its plant-based technology that stops bleeding rapidly, Cresilon has revolutionized the current standards, earning recognition from Fast Company as one of the World's 50 Most Innovative Companies and receiving the EMS World Innovation Awards for TRAUMAGEL.

For more information regarding Cresilon and its products, please visit www.cresilon.com.